UM

Browse/Search Results:  1-2 of 2 Help

Filters    
Selected(0)Clear Items/Page:    Sort:
Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2 Journal article
Bioorganic and Medicinal Chemistry, 2009,Volume: 17,Issue: 2,Page: 731-740
Authors:  Duncton M.A.J.;  Piatnitski Chekler E.L.;  Katoch-Rouse R.;  Sherman D.;  Wong W.C.;  Smith II L.M.;  Kawakami J.K.;  Kiselyov A.S.;  Milligan D.L.;  Balagtas C.;  Hadari Y.R.;  Wang Y.;  Patel S.N.;  Rolster R.L.;  Tonra J.R.;  Surguladze D.;  Mitelman S.;  Kussie P.;  Bohlen P.;  Doody J.F.
Favorite  |  View/Download:2/0  |  Submit date:2019/01/16
Angiogenesis  Arylphthalazine  Inhibitor  KDR  Kinase  Phthalazine  VEGFR-2  
Synthesis and structure-activity relationships of 1,2,4-triazoles as a novel class of potent tubulin polymerization inhibitors Journal article
Bioorganic and Medicinal Chemistry Letters, 2005,Volume: 15,Issue: 23,Page: 5154-5159
Authors:  Ouyang X.;  Chen X.;  Piatnitski E.L.;  Kiselyov A.S.;  He H.-Y.;  Mao Y.;  Pattaropong V.;  Yu Y.;  Kim K.H.;  Kincaid J.;  Smith II L.;  Wong W.C.;  Lee S.P.;  Milligan D.L.;  Malikzay A.;  Fleming J.;  Gerlak J.;  Deevi D.;  Doody J.F.;  Chiang H.-H.;  Patel S.N.;  Wang Y.;  Rolser R.L.;  Kussie P.;  Labelle M.;  Tuma M.C.
Favorite  |  View/Download:1/0  |  Submit date:2019/01/16
1,2,4-Triazole  Antimitotic  Tubulin inhibitor  Tubulin polymerization  Tumor vasculature  Vascular disrupting agent